IRRAS (OM:IRRAS) - Cotización, noticias y análisis

Resumen de acción IRRAS

IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide.

Acerca de la empresa

IRRAS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 62.97%

Análisis de riesgos

Tiene menos de 1 año de cash runway

No tiene una capitalización de mercado significativa (SEK182M)

No tiene ingresos significativos (SEK43M)

Los accionistas han sido diluidos en el último año

+ 1 riesgos adicionales

Competidores de IRRAS AB (publ)

Nanexa

OM:NANEXA

kr125.4m

Ortoma

OM:ORT B

kr294.4m

Phase Holographic Imaging PHI

NGM:PHI

kr169.2m

Medclair

NGM:MCLR

kr92.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for IRRAS
Historical stock prices
Current Share Price	kr0.16
52 Week High	kr0.63
52 Week Low	kr0.11
Beta	1.73
1 Month Change	-6.47%
3 Month Change	-10.39%
1 Year Change	-64.36%
3 Year Change	-97.58%
5 Year Change	-99.58%
Change since IPO	-99.57%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	IRRAS	SE Medical Equipment	Mercado SE
7D	-1.1%	-0.3%	0.9%
1Y	-64.4%	-10.8%	14.4%

Rentabilidad vs. Industria: IRRAS obtuvo unos resultados inferiores a los del sector Swedish Medical Equipment , que el año pasado arrojó un rendimiento del -13.6%.

Rentabilidad vs. Mercado: IRRAS obtuvo unos resultados inferiores a los del mercado Swedish, que fue del 7.8% el año pasado.

Volatilidad de los precios

Is IRRAS's price volatile compared to industry and market?
IRRAS volatility
IRRAS Average Weekly Movement	5.7%
Medical Equipment Industry Average Movement	6.9%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.7%
10% least volatile stocks in SE Market	3.5%

Precio estable de las acciones: IRRAS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IRRAS (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2011	47	Will Martin	www.irras.com

Resumen de fundamentos de IRRAS AB (publ)

¿Cómo se comparan los beneficios e ingresos de IRRAS con su capitalización de mercado?
Estadísticas fundamentales de IRRAS
Capitalización bursátil	kr181.75m
Beneficios(TTM)	-kr196.40m
Ingresos (TTM)	kr43.10m

4.2x

Ratio precio-ventas (PS)

-0.9x

Ratio precio-beneficio (PE)

¿Está IRRAS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IRRAS
Ingresos	kr43.10m
Coste de los ingresos	kr44.03m
Beneficio bruto	-kr935.00k
Otros gastos	kr195.47m
Beneficios	-kr196.40m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

Feb 21, 2024

Beneficios por acción (BPA)	-0.17
Margen bruto	-2.17%
Margen de beneficio neto	-455.71%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado IRRAS a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción IRRAS

Recompensas

Análisis de riesgos

Competidores de IRRAS AB (publ)

OM:NANEXA

kr125.4m

OM:ORT B

kr294.4m

NGM:PHI

kr169.2m

NGM:MCLR

kr92.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00